Literature DB >> 23188077

Prognostic factors in patients with gallbladder cancer after surgical resection: analysis of 279 operated patients.

Hyun Lim1, Dong Wan Seo, Do Hyun Park, Sang Soo Lee, Sung Koo Lee, Myung-Hwan Kim, Shin Hwang.   

Abstract

BACKGROUND: Identification of prognostic factors can help predict life expectancy and decide treatment plan. We evaluated prognostic factors in patients with gallbladder cancer (GBC) after surgical resection. STUDY: Data from 279 patients with GBC who underwent surgery between January 1999 and February 2009 were reviewed retrospectively.
RESULTS: Of the 279 patients, 127 (45.5%) were male; median age was 63 years. R0 resection was achieved in 164 (58.8%) patients, 35 by cholecystectomy and 129 by extended resection. Chemotherapy and radiotherapy were performed in 72 (25.8%) and 55 (19.7%) patients. At a median follow-up of 17.0 months, median overall survival (OS) was 26.0 months. Five-year survival rates for stages I, II, IIIA, IIIB, IVA, and IVB GBC were 94.7%, 75.7%, 44.5%, 21.7%, 4.7%, and 2.6%, respectively. Compared with cholecystectomy, extended resection showed improved OS in all T stages, but statistical significance was observed only in T3 (P<0.001) and T4 (P=0.007). Although OS was similar in patients who received chemotherapy or radiotherapy, radiotherapy significantly improved OS in patients with positive resection margin (P=0.023). Low-grade histologic type (P=0.047) and clear resection margin (P=0.002) were significant predictors of increased OS, but epidemiological factors such as gallstones and anomalous pancreaticobiliary ductal union were not.
CONCLUSIONS: In patients with GBC after surgical resection, TNM stage was the most important prognostic factor. Prognosis was also associated with extent of resection, histologic differentiation, and involvement of resection margin. In patients with positive resection margin, radiotherapy seems to prolong OS.

Entities:  

Mesh:

Year:  2013        PMID: 23188077     DOI: 10.1097/MCG.0b013e3182703409

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  17 in total

1.  Apparent diffusion coefficient as a potential marker for tumour differentiation, staging and long-term clinical outcomes in gallbladder cancer.

Authors:  Ji Hye Min; Tae Wook Kang; Dong Ik Cha; Seong Hyun Kim; Kyung Sook Shin; Jeong Eun Lee; Kee-Taek Jang; Soo Hyun Ahn
Journal:  Eur Radiol       Date:  2018-06-25       Impact factor: 5.315

2.  Therapeutic Potential of Adjuvant Stereotactic Body Radiotherapy for Gallbladder Cancer.

Authors:  Anand Mahadevan; Nergiz Dagoglu; Jennifer F Tseng; Khalid Khawaja; Amy Evenson
Journal:  Cureus       Date:  2015-08-10

3.  Role of Adjuvant Treatment in High-risk Patients Following Resection for Gallbladder Cancer.

Authors:  Younghee Park; Kiryun Kim; Hae Jin Park; Ha-Jung Chun; Dongho Choi; Kyubo Kim
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

4.  Prognostic Factors for Operated Gallbladder Cancer.

Authors:  Bala Basak Oven Ustaalioglu; Ahmet Bilici; Mesut Seker; Umut Kefeli; Dincer Aydin; Serkan Celik; Tarik Demir; Burcak Erkol
Journal:  J Gastrointest Cancer       Date:  2019-09

5.  SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.

Authors:  Edgar Ben-Josef; Katherine A Guthrie; Anthony B El-Khoueiry; Christopher L Corless; Mark M Zalupski; Andrew M Lowy; Charles R Thomas; Steven R Alberts; Laura A Dawson; Kenneth C Micetich; Melanie B Thomas; Abby B Siegel; Charles D Blanke
Journal:  J Clin Oncol       Date:  2015-05-11       Impact factor: 50.717

6.  Clinicopathological features of gallbladder papillary adenocarcinoma.

Authors:  Xueshuai Wan; Haohai Zhang; Cuimin Chen; Xiaobo Yang; Anqiang Wang; Chengpei Zhu; Lilan Fu; Ruoyu Miao; Lian He; Huayu Yang; Haitao Zhao; Xinting Sang
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

7.  Is There a Role for Adjuvant Therapy in R0 Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis.

Authors:  Se-Il Go; Young Saing Kim; In Gyu Hwang; Eun Young Kim; Sung Yong Oh; Jun Ho Ji; Haa-Na Song; Se Hoon Park; Joon Oh Park; Jung Hun Kang
Journal:  Cancer Res Treat       Date:  2016-02-12       Impact factor: 4.679

8.  Long-Term Outcomes and Prognostic Factors in Advanced Gallbladder Cancer: Focus on the Advanced T Stage.

Authors:  Chen Chen; Zhimin Geng; Haoxin Shen; Huwei Song; Yaling Zhao; Guanjun Zhang; Wenzhi Li; Li Ma; Lin Wang
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

9.  Role of common bile duct resection in T2 and T3 gallbladder cancer patients.

Authors:  Jin Hong Lim; Jae Uk Chong; Sung Hoon Kim; Seung Woo Park; Jin Sub Choi; Woo Jung Lee; Kyung Sik Kim
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2018-02-26

10.  Survival benefit of lymphadenectomy for gallbladder cancer based on the therapeutic index: An analysis of the US extrahepatic biliary malignancy consortium.

Authors:  Kota Sahara; Diamantis I Tsilimigras; Shishir K Maithel; Daniel E Abbott; George A Poultsides; Ioannis Hatzaras; Ryan C Fields; Matthew Weiss; Charles Scoggins; Chelsea A Isom; Kamran Idrees; Perry Shen; Itaru Endo; Timothy M Pawlik
Journal:  J Surg Oncol       Date:  2020-01-06       Impact factor: 2.885

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.